Galliford Try (LON:GFRD) Reaches New 52-Week High - Should You Buy?

Galliford Try Holdings plc (LON:GFRD - Get Free Report) shares reached a new 52-week high on Tuesday . The stock traded as high as GBX 398 ($5.18) and last traded at GBX 396 ($5.15), with a volume of 209365 shares traded. The stock had previously closed at GBX 390 ($5.08).

Galliford Try Stock Up 1.5 %

The company has a quick ratio of 0.89, a current ratio of 0.92 and a debt-to-equity ratio of 43.30. The business has a 50-day simple moving average of GBX 322.98 and a 200-day simple moving average of GBX 288.18. The stock has a market cap of £396.79 million, a P/E ratio of 1,114.29, a PEG ratio of 0.90 and a beta of 1.12.

Galliford Try Increases Dividend

The company also recently announced a dividend, which will be paid on Thursday, December 5th. Investors of record on Thursday, November 7th will be paid a GBX 11.50 ($0.15) dividend. The ex-dividend date of this dividend is Thursday, November 7th. This is a positive change from Galliford Try's previous dividend of $4.00. This represents a yield of 3.83%. Galliford Try's dividend payout ratio (DPR) is presently 4,571.43%.

Insiders Place Their Bets

In other Galliford Try news, insider Bill Hocking sold 159,626 shares of the firm's stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of GBX 327 ($4.26), for a total value of £521,977.02 ($679,480.63). Company insiders own 7.70% of the company's stock.

Galliford Try Company Profile

Galliford Try Holdings plc, together with its subsidiaries, operates in the construction business in the United Kingdom. It operates through Building, Infrastructure, and PPP Investments segments. The company engages in the construction of buildings for private and public sector clients in health, education, custodial, and defense markets, as well as serves commercial clients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.